The results of non-randomized clinical trials in urological cancer are often contradictory because of the selection of patients which is usually biased. Such data cannot be used for planning a logical therapy for the future patients. In urological cancer, randomized controlled trials are few. Moreover, antimitotic chemotherapy has not been adequately tried.